Get the Stockscreener App
78.75
3.85%
2.92
After Hours:
79.00
0.25
+0.32%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $78.75, with a volume of 865.73K.
It is up +3.85% in the last 24 hours and up +7.63% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$75.83
Open:
$76.49
24h Volume:
865.73K
Relative Volume:
1.00
Market Cap:
$12.51B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
83.78
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
+5.38%
1M Performance:
+7.63%
6M Performance:
+4.36%
1Y Performance:
+11.99%
1-Day Range:
$76.41
$78.83
1-Week Range:
$73.67
$78.83
52-Week Range:
$61.16
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
78.75 | 12.51B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio - Yahoo Finance
Bio-Techne Earnings Preview: What To Expect - Barchart
Bio-Techne Co. (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio - Yahoo Finance
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine - WV News
Single-use Bioprocessing Probes and Sensors Market Forecast to Reach $10.95 Billion by 2034 - GlobeNewswire Inc.
ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics - Yahoo Finance
GAMMA Investing LLC Buys 333 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bio-Techne wins patent case against Miltenyi Biotec - Investing.com
BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC - Yahoo Finance
3 Genomic Stocks Unlocking the Secrets of DNA - Inkl
BNTX: 3 Genomic Stocks Unlocking the Secrets of DNA - StockNews.com
JPMorgan Chase & Co. Sells 280,782 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
Short Interest in Bio-Techne Co. (NASDAQ:TECH) Drops By 14.0% - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bio-Techne Corp. stock rises Tuesday, still underperforms market - MarketWatch
How Is Bio-Techne’s Stock Performance Compared to Other Biotechnology Stocks? - Nasdaq
How Is Bio-Techne’s Stock Performance Compared To Other Biotechnology Stocks? - Barchart
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain? - Yahoo Finance
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - Financial Times
Bio-Techne Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Bio-Techne partners with Waters for biotherapeutic tech - Investing.com
BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT - Quantisnow
ScaleReady awards a G-Rex® Grant to Moonlight Bio - Quantisnow
Lord Abbett & CO. LLC Has $23.73 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Short Interest Up 15.6% in November - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Toronto Dominion Bank - MarketBeat
Oddo BHF Asset Management Sas Invests $1.19 Million in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Barclays PLC Reduces Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain? - MSN
National Bank of Canada FI Purchases 37,181 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY - Quantisnow
S&P 500 Futures Rise in Premarket Trading; Bausch + Lomb, Bio-Techne Lag - Barron's
West Sac-based GeminiBio acquires a large serum producer's brands, customers - The Business Journals
BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY - Yahoo Finance
Wellington Management Group LLP Sells 147,797 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
State Street Corp Grows Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Tenere Capital LLC Grows Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Worldquant Millennium Advisors LLC Buys 22,185 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Polar Asset Management Partners Inc. Lowers Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Janus Henderson Group PLC Lowers Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Can Mixed Financials Have A Negative Impact on Bio-Techne Corporation's 's (NASDAQ:TECH) Current Price Momentum? - Yahoo Finance
PEAK6 Investments LLC Invests $698,000 in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Exosome Research Products Industry Research Report 2023-2030, Featuring AMS, Bio-Techne, Lonza, Miltenyi Biotech, Nanosomix, Norgen Biotek, NX Pharmagen, Qiagen, SBI, Thermo Fisher Scientific - Yahoo Finance
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):